{
  "metadata": {
    "case_id": 15,
    "model": "GPT-5.1",
    "timestamp": "2025-11-28T05:47:35.626747",
    "total_alignments": 3,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/15_NCT03201419.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/15_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 9,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.73,
          0.35
        ],
        [
          0.68,
          0.4
        ],
        [
          0.78,
          0.12
        ],
        [
          0.82,
          0.33
        ],
        [
          0.78,
          0.12
        ],
        [
          0.83,
          0.48
        ],
        [
          0.2,
          0.78
        ],
        [
          0.78,
          0.3
        ],
        [
          0.72,
          0.4
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "FE 201836 500 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily",
            "interventionNames": [
              "Drug: FE 201836",
              "Drug: Placebo ODT"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "FE 201836 350 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "FE 201836 350 μg oral solution and placebo ODT, administered once daily",
            "interventionNames": [
              "Drug: FE 201836",
              "Drug: Placebo ODT"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "FE 201836 250 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "FE 201836 250 μg oral solution and placebo ODT, administered once daily",
            "interventionNames": [
              "Drug: FE 201836",
              "Drug: Placebo ODT"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "FE 201836 150 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "FE 201836 150 μg oral solution and placebo ODT, administered once daily",
            "interventionNames": [
              "Drug: FE 201836",
              "Drug: Placebo ODT"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "FE 201836 100 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "FE 201836 100 μg oral solution and placebo ODT, administered once daily",
            "interventionNames": [
              "Drug: FE 201836",
              "Drug: Placebo ODT"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 5,
          "pred_idx": 0,
          "score": 0.83,
          "status": "matched",
          "ref_item": {
            "label": "FE 201836 50 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "FE 201836 50 μg oral solution and placebo ODT, administered once daily",
            "interventionNames": [
              "Drug: FE 201836",
              "Drug: Placebo ODT"
            ]
          },
          "pred_item": {
            "label": "Novel drug for nocturnal polyuria",
            "type": "EXPERIMENTAL",
            "description": "Participants received a novel investigational pharmacologic treatment for nocturnal polyuria as part of a randomized, double-blind, placebo-controlled, multicenter Phase 2 clinical trial. The NI Diary and nocturnal voiding diary were completed during treatment to assess impact on nocturia-related quality of life.",
            "interventionNames": [
              "Novel drug for nocturnal polyuria"
            ]
          }
        },
        {
          "ref_idx": 6,
          "pred_idx": 1,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "label": "Placebo (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "Placebo oral solution and placebo ODT, administered once daily",
            "interventionNames": [
              "Drug: Placebo oral solution",
              "Drug: Placebo ODT"
            ]
          },
          "pred_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants received placebo in a randomized, double-blind, placebo-controlled, multicenter Phase 2 clinical trial of a novel drug for nocturnal polyuria. The NI Diary and nocturnal voiding diary were completed during treatment to assess impact on nocturia-related quality of life.",
            "interventionNames": [
              "Placebo"
            ]
          }
        },
        {
          "ref_idx": 7,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Desmopressin 25 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)",
            "interventionNames": [
              "Drug: Desmopressin",
              "Drug: Placebo oral solution"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 8,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Desmopressin 50 μg (Randomized Treatment Period)",
            "type": "EXPERIMENTAL",
            "description": "Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)",
            "interventionNames": [
              "Drug: Desmopressin",
              "Drug: Placebo oral solution"
            ]
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.7,
          0.2
        ],
        [
          0.4,
          0.5
        ],
        [
          0.3,
          0.93
        ],
        [
          0.4,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.7,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "FE 201836",
            "description": "Oral solution for daily intake",
            "armGroupLabels": [
              "FE 201836 100 μg (Randomized Treatment Period)",
              "FE 201836 150 μg (Randomized Treatment Period)",
              "FE 201836 250 μg (Randomized Treatment Period)",
              "FE 201836 350 μg (Randomized Treatment Period)",
              "FE 201836 50 μg (Randomized Treatment Period)",
              "FE 201836 500 μg (Randomized Treatment Period)"
            ],
            "otherNames": [
              "Velmupressin"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Novel drug for nocturnal polyuria",
            "description": "An investigational pharmacologic agent evaluated in the DAWN Phase 2 randomized, double-blind, placebo-controlled trial for treatment of nocturnal polyuria and associated nocturia. Specific compound name, dose, and regimen are not provided in the text.",
            "armGroupLabels": [
              "Novel drug for nocturnal polyuria"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "type": "DRUG",
            "name": "Desmopressin",
            "description": "Desmopressin Orally Disintegrating Tablet (ODT)",
            "armGroupLabels": [
              "Desmopressin 25 μg (Randomized Treatment Period)",
              "Desmopressin 50 μg (Randomized Treatment Period)"
            ],
            "otherNames": [
              "NOCDURNA"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo oral solution",
            "description": "Manufactured to mimic experimental drug",
            "armGroupLabels": [
              "Desmopressin 25 μg (Randomized Treatment Period)",
              "Desmopressin 50 μg (Randomized Treatment Period)",
              "Placebo (Randomized Treatment Period)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Placebo comparator administered in the DAWN Phase 2 randomized, double-blind, placebo-controlled trial evaluating a novel drug for nocturnal polyuria.",
            "armGroupLabels": [
              "Placebo"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo ODT",
            "description": "Manufactured to mimic experimental drug",
            "armGroupLabels": [
              "FE 201836 100 μg (Randomized Treatment Period)",
              "FE 201836 150 μg (Randomized Treatment Period)",
              "FE 201836 250 μg (Randomized Treatment Period)",
              "FE 201836 350 μg (Randomized Treatment Period)",
              "FE 201836 50 μg (Randomized Treatment Period)",
              "FE 201836 500 μg (Randomized Treatment Period)",
              "Placebo (Randomized Treatment Period)"
            ]
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment",
            "description": "Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.\n\nThe number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.\n\nLevel estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.",
            "timeFrame": "Baseline, during 12 weeks of treatment"
          },
          "pred_item": {
            "measure": "Reduction in nocturnal voids",
            "description": "Change in the average number of nocturnal voids per night, derived from the night-time voiding diary. This was the primary endpoint for the Phase 2 DAWN trial, used here as a clinical anchor in psychometric analyses.",
            "timeFrame": "Baseline to Week 12 (average over the three nights preceding each clinic visit)"
          }
        }
      ]
    }
  ]
}